Skip to main content

Advertisement

SpringerLink
Log in

Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma

  • Clinical trial
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Background

Localized breast angiosarcoma (LBA) is a rare condition with no prospective clinical trials guiding the management of afflicted patients. Management of LBA and the resulting outcomes on a nationwide scale has not been previously examined.

Methods

The National Cancer Data Base (NCDB) from 2004 to 2014 identified resected LBA patients. Treatment patterns were compared between three time periods (2004–2007, 2008–2011, and 2012–2014). Demographic and tumor characteristics, as well as treatments received—extent of surgery and adjuvant therapies—were analyzed for association with overall survival after adjustment for covariates.

Results

826 resected localized breast angiosarcoma patients were identified. Mastectomy was the most common surgical approach (86%); over 60% of patients did not receive adjuvant therapies after surgery. On multivariate analysis, tumor grade, tumor size, and surgical margins were associated with worse survival. Extent of surgery (mastectomy versus lumpectomy) and radiation therapy use were not associated with improved survival. Adjuvant chemotherapy was associated with improved survival in patients with primary tumors 5 cm and greater.

Conclusions

The extent of surgery is not associated with improved survival in women with LBA, and patients may consider breast-conservation surgery. Adjuvant therapies are not associated with improved survival, with the exception of possible role of adjuvant chemotherapy in large primary tumors (5 cm or greater). Further clinical studies are needed to determine the impact of these treatments on local control, progression-free survival, and patients’ quality of life. Until then, the findings of our analysis will form basis for the multi-disciplinary discussion of management of women with LBA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Antonescu CR, Yoshida A, Guo T et al (2009) KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 69:7175–7179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Wang XY, Jakowski J, Tawfik OW, Thomas PA, Fan F (2009) Angiosarcoma of the breast: a clinicopathologic analysis of cases from the last 10 years. Ann Diagn Pathol 13:147–150

    Article  PubMed  Google Scholar 

  3. Brentani MM, Pacheco MM, Oshima CT (1983) Steroid receptor in breast angiosarcoma. Cancer 51:2105–2111

    Article  CAS  PubMed  Google Scholar 

  4. Donnell RM, Rosen PP, Lieberman PH et al (1981) Angiosarcoma and other vascular tumors of the breast: pathologic analysis as a guide to prognosis. Am J Surg Pathol 5:629–642

    Article  CAS  PubMed  Google Scholar 

  5. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ (2010) Angiosarcoma Lancet Oncol 11:983–991

    Article  PubMed  Google Scholar 

  6. Scow JS, Reynolds CA, Degnim AC, Petersen IA, Jakub JW, Boughey JC (2010) Primary and secondary angiosarcoma of the breast: the Mayo Clinic experience. J Surg Oncol 101:401–407

    PubMed  Google Scholar 

  7. American College of Surgeons Commission on Cancer (2011) National cancer data base, 2008 data submission. American College of Surgeons, Chicago

    Google Scholar 

  8. Park HS, Wang EH, Rutter CE, Corso CD, Chiang VL, Yu JB (2016) Changing practice patterns of Gamma Knife versus linear accelerator-based stereotactic radiosurgery for brain metastases in the US. J Neurosurg 124:1018–1024

    Article  CAS  PubMed  Google Scholar 

  9. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40:373–383

    Article  CAS  Google Scholar 

  10. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619

    Article  CAS  PubMed  Google Scholar 

  11. Hatfield J, McClelland S 3rd, Luo J et al (2018) Management of localized breast angiosarcoma by North American radiation and medical oncologists. Clin Breast Cancer 18:498–503

    Article  PubMed  Google Scholar 

  12. Le Cesne A, Ouali M, Leahy MG et al (2014) Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 25:2425–2432

    Article  PubMed  Google Scholar 

  13. Grobmyer SR, Maki RG, Demetri GD et al (2004) Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 15:1667–1672

    Article  CAS  PubMed  Google Scholar 

  14. Mullen JT, Kobayashi W, Wang JJ et al (2012) Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer 118:3758–3765

    Article  PubMed  Google Scholar 

  15. Toomey PG, Teta AF, Patel KD, Ross SB, Rosemurgy AS (2016) High-volume surgeons vs high-volume hospitals: are best outcomes more due to who or where? Am J Surg 211:59–63

    Article  PubMed  Google Scholar 

  16. McClelland S 3rd, Guo H, Okuyemi KS (2011) Morbidity and mortality following acoustic neuroma excision in the USA: analysis of racial disparities during a decade in the radiosurgery era. Neuro Oncol 13:1252–1259

    Article  PubMed  PubMed Central  Google Scholar 

  17. Chang HT, Shi HY, Wang BW, Yeh SJ (2017) Breast cancer incidence and predictors of surgical outcome: a nationwide longitudinal study in Taiwan. Clin Oncol (R Coll Radiol) 29:362–369

    Article  Google Scholar 

  18. Yin M, Wang W, Drabick JJ, Harold HA (2017) Prognosis and treatment of non-metastatic primary and secondary breast angiosarcoma: a comparative study. BMC Cancer 17:295

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bilimoria KY, Bentrem DJ, Stewart AK, Winchester DP, Ko CY (2009) Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. J Clin Oncol 27:4177–4181

    Article  PubMed  Google Scholar 

Download references

Funding

This study was not funded.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Indiana University School of Medicine, 535 Barnhill Drive, RT 041, Indianapolis, IN, 46202, USA

    Shearwood McClelland III

  2. Department of Radiation Medicine, Oregon Health and Science University, Portland, OR, USA

    Shearwood McClelland III, Jess Hatfield & Timur Mitin

  3. Biostatistics Shared Resource, Oregon Health and Science University, Portland, OR, USA

    Catherine Degnin & Yiyi Chen

Authors
  1. Shearwood McClelland III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jess Hatfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Catherine Degnin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yiyi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Timur Mitin
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

McClelland: conceptualization, funding acquisition, investigation, methodology, project administration, resources, software, validation, visualization, writing—original draft, and writing—review and editing. Hatfield: investigation, methodology, project administration, resources, software, validation, visualization, and writing—review and editing. Degnin and Chen: data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, and writing—review and editing. Mitin: conceptualization, funding acquisition, investigation, methodology, project administration, resources, software, supervision, validation, visualization, and writing—review and editing.

Corresponding author

Correspondence to Shearwood McClelland III.

Ethics declarations

Conflict of interest

Dr. Mitin receives research support from Novocure. No other author has any financial disclosures.

Research involving human participants and/or animals

All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

McClelland, S., Hatfield, J., Degnin, C. et al. Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma. Breast Cancer Res Treat 175, 409–418 (2019). https://doi.org/10.1007/s10549-019-05172-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-019-05172-5

Keywords

Search

Navigation